{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:48:31Z","timestamp":1785473311244,"version":"3.56.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s13555-024-01171-7","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T20:19:53Z","timestamp":1716409193000},"page":"1561-1573","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0771","authenticated-orcid":false,"given":"Jos\u00e9-Manuel","family":"Carrascosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Narcisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9954-6446","authenticated-orcid":false,"given":"Toshifumi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3612-7786","authenticated-orcid":false,"given":"Sonja","family":"St\u00e4nder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6485-3158","authenticated-orcid":false,"given":"Christian","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Grond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uffe","family":"Koppelhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elrayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Fei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0177-8722","authenticated-orcid":false,"given":"Andreas","family":"Wollenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,22]]},"reference":[{"key":"1171_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","volume":"70","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70:338\u201351.","journal-title":"J Am Acad Dermatol"},{"key":"1171_CR2","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121:340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1171_CR3","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1016\/j.jaci.2017.01.008","volume":"139","author":"T Bieber","year":"2017","unstructured":"Bieber T, D\u2019Erme AM, Akdis CA, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should we go? J Allergy Clin Immunol. 2017;139:S58-64.","journal-title":"J Allergy Clin Immunol"},{"key":"1171_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","volume":"21","author":"T Bieber","year":"2022","unstructured":"Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21:21\u201340.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"1171_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40257-022-00697-w","volume":"23","author":"R Chovatiya","year":"2022","unstructured":"Chovatiya R, Silverberg JI. Evaluating the longitudinal course of atopic dermatitis: implications for clinical practice. Am J Clin Dermatol. 2022;23(4):459\u201368.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1171_CR6","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra2023911","volume":"384","author":"S St\u00e4nder","year":"2021","unstructured":"St\u00e4nder S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136\u201343.","journal-title":"N Engl J Med"},{"issue":"1","key":"1171_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.anai.2021.03.019","volume":"127","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, Lei D, Ahmed A, et al. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol. 2021;127(1):83\u201390.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1171_CR8","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1007\/s12325-023-02528-8","volume":"40","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, de Bruin-Weller M, Costanzo A, et al. Baseline body surface area and itch severity define response to baricitinib in patients with moderate-to-severe atopic dermatitis at week 16. Adv Ther. 2023;40:3574\u201387.","journal-title":"Adv Ther"},{"key":"1171_CR9","unstructured":"Olumiant. European Union Summary of Product Characteristics. Eli Lilly and Company. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/olumiant-eparproductinformation_en.pdf."},{"issue":"9","key":"1171_CR10","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I\u2014systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1171_CR11","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/03007995.2021.1933929","volume":"37","author":"M Iannone","year":"2021","unstructured":"Iannone M, Tonini G, Janowska A, et al. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review. Curr Med Res Opin. 2021;37(8):1295\u2013301.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1171_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jaci.2014.07.043","volume":"134","author":"J Schmitt","year":"2014","unstructured":"Schmitt J, Spuls PI, Thomas KS, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4):800\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"1171_CR13","doi-asserted-by":"publisher","first-page":"943","DOI":"10.36849\/JDD.2020.5422","volume":"19","author":"PA Lio","year":"2020","unstructured":"Lio PA, Wollenberg A, Thyssen JP, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. JDD. 2020;19(10):943\u20138.","journal-title":"JDD"},{"issue":"4","key":"1171_CR14","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1684\/ejd.2022.4280","volume":"32","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Lio P, Kleyn E, et al. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III trials. Eur J Dermatol. 2022;32(4):522\u20139.","journal-title":"Eur J Dermatol"},{"issue":"7","key":"1171_CR15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/14712598.2023.2224499","volume":"23","author":"N Gori","year":"2023","unstructured":"Gori N, Ippoliti E, Peris K, Chiricozzi A. Head and neck atopic dermatitis: still a challenging manifestation in the biologic era. Expert Opin Biol Ther. 2023;23(7):575\u20137.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"1171_CR16","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.jaad.2021.01.012","volume":"84","author":"CE Jo","year":"2021","unstructured":"Jo CE, Finstad A, Georgakopoulos JR, et al. Facial and neck erythema associated with dupilumab treatment: a systematic review. J Am Acad Dermatol. 2021;84(5):1339\u201347.","journal-title":"J Am Acad Dermatol"},{"key":"1171_CR17","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis. JAMA Dermatol. 2020;156:1333\u201343.","journal-title":"JAMA Dermatol"},{"key":"1171_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","volume":"33","author":"JM Hanifin","year":"2022","unstructured":"Hanifin JM, Baghoomian W, Grinich E, et al. The eczema area and severity index\u2014a practical guide. Dermatitis. 2022;33:187\u201392.","journal-title":"Dermatitis"},{"key":"1171_CR19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1111\/bjd.17703","volume":"181","author":"A Blauvelt","year":"2019","unstructured":"Blauvelt A, Rosmarin D, Bieber T, et al. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials. BJD. 2019;181:196\u20137.","journal-title":"BJD"},{"key":"1171_CR20","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.16763","volume":"50","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, et al. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023;50:869\u201379.","journal-title":"J Dermatol"},{"key":"1171_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19669","author":"A Wollenberg","year":"2023","unstructured":"Wollenberg A, Simon D, Kulthanan K, et al. Baricitinib treatment rapidly improves the four signs of atopic dermatitis assessed by Eczema Area and Severity Index (EASI) clinical subscores. J Eur Acad Dermatol Venereol. 2023. https:\/\/doi.org\/10.1111\/jdv.19669. (Epub ahead of print).","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"1171_CR22","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1111\/exd.14368","volume":"30","author":"S Ribero","year":"2021","unstructured":"Ribero S, Puglisi B, Giura MT, et al. Head and neck severity index is associated to a significant worsening of quality of life in atopic dermatitis patients. Exp Derm. 2021;30(11):1717\u20138.","journal-title":"Exp Derm"},{"key":"1171_CR23","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37:1046\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1171_CR24","unstructured":"Maintz L, Schmitz M-T, Herrmann N, et al. Real-world data on short-term effectiveness, clinician- & patient-reported outcomes in patients with atopic dermatitis treated with baricitinib. Poster presented at EADV-Spring symposium, 18\u201320 May 2023, Seville, Spain."},{"key":"1171_CR25","unstructured":"Pinter A, Reguiai Z, Werfel T, et al. Baricitinib outcomes on atopic dermatitis lesion locations: results from a cross-sectional patient survey in France, Germany, and the United Kingdom. Poster presented at EADV symposium, 11\u201314 October 2023, Berlin, Germany."},{"issue":"1","key":"1171_CR26","doi-asserted-by":"publisher","first-page":"2276047","DOI":"10.1080\/09546634.2023.2276047","volume":"34","author":"M Augustin","year":"2023","unstructured":"Augustin M, Nosbaum A, Werfel T, et al. Treatment satisfaction of adult patients with moderate-to-severe atopic dermatitis treated with baricitinib in France, Germany, and the United Kingdom: Results from a cross-sectional patient survey. J Dermatol Treat. 2023;34(1):2276047.","journal-title":"J Dermatol Treat"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01171-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01171-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01171-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T13:04:27Z","timestamp":1718197467000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01171-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,22]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01171-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,22]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jose Manuel Carrascosa has received grants, consulting fees, speaker honoraria, travel support and\/or served on an advisory board for AbbVie, Almirall, Bristol-Myers Squibb, Eli Lilly and Company, Galderma, Janssen, IB Pharma, LEO Pharma, Novartis, Pfizer, Sandoz, Sanofi, and UCB. Alessandra Narcisi has received consulting fees, speaker honoraria, and\/or travel support from AbbVie, Almirall, Amgen, Boehringer, Eli Lilly and Company, LEO Pharma, Pfizer, Sanofi, and UCB. Toshifumi Nomura has received speaker honoraria from Eli Lilly and Company. Sonja St\u00e4nder has received grants, consulting fees, speaker honoraria, travel support, and\/or served on an advisory board for AbbVie, Almirall, Beiersdorf, Bristol-Myers Squibb, Clexio, Eli Lilly and Company, Escient, FomF, Galderma, Gr\u00fcnenthal, Incyte, IntegrityCE, Kiniksa, Klinge Pharma, LEO Pharma, L\u2019Oreal, MEDahead, Moroscience, Novartis, Pfizer, P.G. Unna Academy, Sanofi, TouchIME, Vifor, and WebMD. Christian Vestergaard has received consulting fees, speaker honoraria, and\/or research support from AbbVie, Eli Lilly and Company, LEO Pharma, Novartis, and Sanofi. Silvia Sabatino, Susanne Grond, Uffe Koppelhus, Mohamed Elrayes, and Yun-Fei Chen are employees and minor shareholders of Eli Lilly and Company. Chunyuan Liu is an employee of TigerMed-BDM Inc. and under long-term contract as a statistical expert for Eli Lilly and Company. Andrea Wollenberg has received grants, consulting fees, and\/or study support from AbbVie, Aileens, Almirall, Beiersdorf, Eli Lilly and Company, Galapagos, Galderma, Glenmark, GSK, Janssen, LEO Pharma, L\u2019Oreal, MedImmune, MSD, Novartis, Pfizer, Pierre Fabre, Regeneron, Sanofi, and UCB.  Chunyuan Liu is an employee of TigerMed-BDM Inc and under contract with Eli Lilly and Company. He is not a Lilly shareholder.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Protocols for all studies included in this analysis were approved by the Institutional Review Board or Ethics Committee at each participating site. All studies included in this analysis were conducted in accordance with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all eligible participants before undergoing study-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}